PB 77 of 2021
National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 7)
I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.
Dated 27 July 2021
NIKOLAI TSYGANOV
Assistant Secretary (Acting)
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
1 Name
(1) This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 7).
(2) This instrument may also be cited as PB 77 of 2021.
2 Commencement
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information |
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 August 2021 | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 89A(3) of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Continued Dispensing – Emergency Measures) Determination 2020
[1] Schedule 1, after entry for Adrenaline (epinephrine) in the form Injection 1 mg (as acid tartrate) in 1 mL (1 in 1,000)
insert:
| Solution for injection 1 mg (as tartrate) in 1 mL (1 in 1,000) | Injection |
[2] Schedule 1, after entry for Alendronic acid with colecalciferol and calcium
insert:
Alirocumab | Injection 75 mg in 1 mL single use pre-filled pen | Injection |
| Injection 150 mg in 1 mL single use pre-filled pen | Injection |
[3] Schedule 1, entry for Exenatide
omit:
| Injection (modified release) 2 mg single dose pre-filled pen | Injection |
[4] Schedule 1, after entry for Framycetin
insert:
Fremanezumab | Solution for injection 225 mg in 1.5 mL single dose pre-filled syringe | Injection |
[5] Schedule 1, entry for Paraffin
insert as first entry:
| Eye drops containing liquid paraffin, glycerol, tyloxapol, poloxamer-188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free) | Application to the eye |